Try our beta test site
1360 studies found for:    Open Studies | Lymphoma OR CLL
Show Display Options
Rank Status Study
1 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Condition: LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Intervention: Biological: CART 19
2 Recruiting A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Interventions: Drug: Ibrutinib;   Drug: Fludarabine
3 Recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment;   Biological: Trivalent Influenza Vaccine
4 Recruiting A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL(Mantle Cell Lymphoma), DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Drug: AC0010MA
5 Recruiting Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Follicular Lymphoma
Intervention: Drug: ME-401
6 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
7 Recruiting Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Conditions: Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
Interventions: Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
8 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
9 Recruiting Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: dimethyl fumarate
10 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
11 Recruiting A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
Condition: CLL
Intervention: Drug: GA101/HDMP
12 Recruiting Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: acalabrutinib
13 Recruiting Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Atezolizumab
14 Recruiting Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukaemia (CLL);   B-Cell Non-Hodgkin Lymphoma (NHL);   Multiple Myeloma (MM)
Intervention: Drug: S 55746
15 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia;   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia;   Splenic Marginal Zone Lymphoma
Intervention:
16 Recruiting Heavy Light Chain in Chronic Lymphocytic Leukemia
Condition: CLL
Intervention: Other: No intervantion
17 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
18 Recruiting A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single-dose Obinutuzumab Pretreatment, in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Conditions: Lymphocytic Leukemia, Chronic;   Lymphoma, Non Hodgkin
Interventions: Drug: BTCT4465A;   Drug: Obinutuzumab
19 Not yet recruiting Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia
Condition: CLL
Intervention: Other: there will be no intervention.
20 Recruiting Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Conditions: Lymphoma;   Myeloma;   Leukemia
Intervention: Biological: Kappa CD28 T cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.